7 December 2022 in Discover Oncology
Background: Spi-1 proto-oncogene (SPI1), which encodes an ETS-domain transcription factor, can activate gene expression in myeloid and lymphoid lineages. The role of SPI1 in the tumor immune microenvironment in clear cell renal cell carcinoma (ccRCC) remains unknown. In this study, we investigated the possible role of SPI1 in ccRCC using an independent cohort and a comprehensive bioinformatics analysis. Materials and methods: Quantitative real-time PCR, western blot and immunohistochemistry assays were used to compare the SPI1 expression levels between ccRCC tissues and normal tissues, analyze the relationships between SPI1 and CD68, CD8, CD4 expression levels, and explore the link between SPI1 and the efficacy of immunotherapy in our cohort. Tumor Immune Estimation Resource, UALCAN, cBioPortal, TISIDB database, and LinkedOmics database were used in our study. Results: SPI1 expression level was higher in ccRCC bulk tissues than in normal bulk tissues. SPI1 was an independent prognostic factor for poor overall survival and progression-free survival in patients with ccRCC. SPI1 expression was strongly related to the infiltration of immune cells and immune-related molecules. SPI1 was more highly expressed in tumor-infiltrating immune cells rather than in cancer cells. Non-responders to immunotherapy against ccRCC were more likely to express higher SPI1 levels than responders. Genes co-expressed with SPI1 primarily correlated with immune-related pathways. Conclusions: SPI1 expression in tumor bulk tissues is associated with disease progression and poor prognosis, as well as high expression levels of immune markers and infiltration of immune cells. SPI1 can be used as a prognostic biomarker to monitor and evaluate immunotherapy efficacy.
8 December 2021 in Frontiers in Oncology
Backgrounds: CD146 is highly expressed in various malignant tumors and associated with the poor prognosis. However, the role of CD146 in clear cell renal cell carcinoma (ccRCC) is still unknown. This study aimed to identify the role of CD146 in ccRCC by integrated bioinformatics analysis. Methods: CD146 mRNA expression and methylation data in ccRCC was examined using the TIMER, UALCAN, and MethSurv databases. CD146 expression in paraffin-embedded tissues (140 cancer samples and 140 paracancer tissues) from our cohort were examined by immunohistochemistry assay. The LinkedOmics database was used to study the signaling pathways related to CD146 expression. TIMER and TISIDB were used to analyze the correlations among CD146, CD146-coexpressed genes, tumor-infiltrating immune cells, and immunomodulators. The relationship between CD146 and drug response in renal cancer cell lines was analyzed by the CTRP and CCLE databases. Results: The mRNA and protein levels of CD146 were elevated in ccRCC tissues than that in paracancer tissues. The DNA methylation of CD146 in ccRCC tissues were lower than that in normal tissues. Importantly, high CD146 expression was associated with poor prognosis in patients with ccRCC. Furthermore, multivariate Cox regression analysis showed that CD146 was an independent prognostic factor in ccRCC. GO and KEGG pathway analyses indicated the co-expressed genes of CD146 were mainly related to a variety of immune-related pathways, including Th1 and Th2 cell differentiation, Th17 cell differentiation, and leukocyte transendothelial migration. Our data demonstrated that the expression and methylation status of CD146 were strongly correlated with immune infiltration levels, immunomodulators, and chemokines. Further, the sensitivity and resistance of renal cancer cell lines to some drugs were related to CD146 expression. Conclusions: Our study highlights the clinical significance of CD146 in ccRCC and provides novel insights into the immune function of CD146 in the tumor microenvironment.
15 January 2022 in Urologic Oncology: Seminars and Original Investigations
30 August 2021 in Research Square
Objectives: To evaluate the prognostic value of preoperative lymphocyte to monocyte ratio (LMR) in patients with renal cell carcinoma and venous tumor thrombus (RCC-VTT) after surgery. Methods: We retrospectively reviewed the medical data of 144 consecutive patients with RCC and level I-IV VTT after surgery. Kaplan-Meier method was used to assess and compare survival. Univariable and multivariable Cox proportional hazard models were constructed to identify the independent prognostic factor for survival. The Harrell concordance index was used to assess the predictive accuracy. Results: Decreased preoperative LMR was significantly correlated with clinicopathologic features that are associated with tumor progression. Decreased preoperative LMR was an independently risk factor for decreased OS (P < 0.05) and PFS (P < 0.05). To evaluate PFS, integrating LMR to each model led to an increased predictive accuracy of 6.9% for TNM staging model (P = 0.014), 6.8% for UISS model (P = 0.006), 3.4% for SSIGN model (P = 0.017), respectively. Incorporating LMR into SSIGN model led to an increased predictive accuracy of 6.5% for OS (P < 0.001). Conclusions: Preoperative LMR is an independent prognostic factor for patients with RCC-VTT after surgery. Adding preoperative LMR to the prognostic models enhance their predictive accuracy.